Aptose Biosciences Stock Forecast for 2023 - 2025 - 2030
Updated on 04/29/2024
Aptose Biosciences Stock Forecast and Price Target
Given the average yearlong price target of C$0.88 provided by four prominent analysts over the past few months, there is a potential downside of approximately -46.67% from the last closing price in April, 2024 for Aptose Biosciences's stock if it is reached. This estimation is based on a high estimate of C$0.98 and a low estimate of C$0.78. If you're looking for information on Aptose Biosciences stock, consider checking out the forecasts for comparable firms such as NasdaqGM:AUPH.
-46.67% Downside
Aptose Biosciences Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Aptose Biosciences's Price has grown, increasing from C$0.00 to C$0.00 – a growth of 100.00%. The next year looks promising for Aptose Biosciences, with analysts predicting Fair Value of C$1.75 – an increase of 100.00%. Over the next seven years, experts anticipate that Aptose Biosciences's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| XENE Stock Forecast | Xenon Pharmaceuticals | Buy |
11
|
$42.73 | Buy/Sell | $51.46 | 40.42% |
| ZYME Stock Forecast | Zymeworks | Outperform |
7
|
$8.33 | Buy/Sell | $13.52 | 68.07% |
| AUPH Stock Forecast | Aurinia Pharmaceuticals | Outperform |
6
|
$5.01 | Buy/Sell | $13.21 | 99.60% |
| EPIX Stock Forecast | ESSA Pharma | Buy |
5
|
$6.14 | Buy/Sell | $26.91 | 273.94% |
| ACHF.F Stock Forecast | Arch Biopartners | - |
4
|
$1.12 | Buy/Sell | $0.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CRDL Stock Forecast | Cardiol Therapeutics | Outperform |
7
|
C$2.41 | Buy/Sell | C$4.50 | 86.72% |
| SVA Stock Forecast | Sernova | Outperform |
5
|
C$0.43 | Buy/Sell | C$4.07 | 667.44% |
| MIST Stock Forecast | Milestone Pharmaceuticals | Outperform |
4
|
$1.57 | Buy/Sell | $10.80 | 345.86% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MDNA Stock Forecast | Medicenna Therapeutics | Buy |
0
|
C$2.31 | Buy/Sell | C$6.30 | 289.61% |
| PMN Stock Forecast | ProMIS Neurosciences | Buy |
6
|
$2.00 | Buy/Sell | $18.49 | 501.00% |
| BCT Stock Forecast | BriaCell Therapeutics | Outperform |
4
|
C$2.95 | Buy/Sell | C$0.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IPA Stock Forecast | ImmunoPrecise Antibodies | Buy |
9
|
$1.37 | Buy/Sell | $7.00 | 410.95% |
| MBX Stock Forecast | Microbix Biosystems | Buy |
0
|
C$0.43 | Buy/Sell | C$0.00 | 86.05% |
| IBT Stock Forecast | IBEX Technologies | - |
0
|
C$1.44 | Buy/Sell | C$0.70 | -100.00% |
Aptose Biosciences EBITDA Forecast for 2023 - 2025 - 2030
Aptose Biosciences's EBITDA has decreased by 23.62% In the last two years, from C$-55.62M to C$-42.48M. For next year, analysts predict EBITDA of C$-83.74M, which would mean an increase of 97.13%. Over the next seven years, experts predict that Aptose Biosciences's EBITDA will grow at a rate of 86.74%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TBPM.Q Stock Forecast | Tetra Bio-Pharma | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
| BU Stock Forecast | Burcon NutraScience | - |
0
|
C$0.27 | Buy/Sell | C$2.50 | -100.00% |
| COV Stock Forecast | Covalon Technologies | - |
0
|
C$1.01 | Buy/Sell | C$0.00 | -100.00% |
Aptose Biosciences EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Aptose Biosciences's EBIT has decreased from C$-55.77M to C$-42.60M – a 23.61% drop! For next year, analysts predict EBIT of C$-87.39M, which would mean an increase of 105.14%. In 2030, professionals predict that Aptose Biosciences's EBIT will decrease by 928.57%, reaching C$352.97M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 20B Stock Forecast | Biomark Diagnostics | - |
0
|
0.18€ | Buy/Sell | 0.00€ | -100.00% |
| SBM Stock Forecast | Sirona Biochem | - |
-10
|
C$0.06 | Buy/Sell | C$0.95 | -100.00% |
| EDSA Stock Forecast | Edesa Biotech | Buy |
-17
|
$4.37 | Buy/Sell | $36.67 | 380.55% |
Aptose Biosciences EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Aptose Biosciences's EPS has grown, increasing from C$-12.62 to C$0.00 – a growth of 100.00%. The next year looks promising for Aptose Biosciences, with analysts predicting EPS of C$-7.75 – an increase of 100.00%. Over the next seven years, experts anticipate that Aptose Biosciences's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| RVX Stock Forecast | Resverlogix | - |
0
|
C$0.07 | Buy/Sell | C$0.00 | -100.00% |
| MVMD Stock Forecast | Mountain Valley MD Holdings | - |
-16
|
C$0.06 | Buy/Sell | C$0.00 | -100.00% |
| KNE Stock Forecast | Kane Biotech | - |
0
|
C$0.13 | Buy/Sell | C$0.00 | -100.00% |
.jpg)